The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email [email protected]. MyChart is a ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Applies to most patients with one or two positive sentinel lymph nodes ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Multicenter, prospective study of radiotherapy without surgery after AC followed by weekly paclitaxel for patients with inflammatory breast cancer: SBCCSG-04 study No significant financial ...

SAN ANTONIO -- Neoadjuvant chemotherapy that downstaged positive lymph nodes to negative led to a low rate of invasive breast cancer recurrence with either targeted axillary dissection (TAD) or ...

Through the use of preoperative axillary ultrasound (AUS), more patients with clinical node‑positive (cNI) breast cancer and ...

Prospective Multicentric Randomized Study Comparing Periareolar and Peritumoral Injection of Radiotracer and Blue Dye for the Detection of Sentinel Lymph Node in Breast Sparing Procedures: FRANSENODE ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...